AA amyloidosis

Lore & Background

AA amyloidosis arises as a complication of various chronic inflammatory conditions, autoimmune diseases, infections, and certain cancers. The deposited protein is serum amyloid A (SAA), an acute-phase reactant that can rise from a median plasma concentration of 3 mg per liter in healthy individuals to over 2000 mg per liter during inflammation. Sustained overproduction of SAA is required for the formation of AA deposits, though high SAA levels alone are not sufficient, and the trigger for accumulation remains unclear.

Reader's Guide

AA amyloidosis is significant as a serious complication of chronic inflammatory and infectious diseases, with renal involvement being the most common presentation, often leading to proteinuria, nephrotic syndrome, and progressive chronic kidney disease that may require dialysis or kidney transplantation. Diagnosis is typically made via tissue biopsy of subcutaneous abdominal fat, rectal mucosa, or minor salivary glands, with immunochemical staining needed to distinguish it from other amyloidoses. There are no approved treatments specifically for systemic AA amyloidosis; current standard care focuses on treating the underlying inflammatory disease with anti-inflammatory drugs, immunosuppressive agents, or biologics, along with measures to slow renal decline such as angiotensin II receptor blockers or ACE inhibitors. Prognosis is poorer with old age, reduced serum albumin, end stage kidney failure, and sustained elevated SAA concentration. The potential for transmission via ingestion of amyloid fibers has been observed in animals, raising concerns but remaining unconfirmed in humans.

Did You Know?

• The median plasma concentration of SAA in a healthy individual is 3 mg per liter, which can increase to over 2000 mg per liter during an acute phase response.
• AA amyloidosis commonly affects the kidneys, liver, and spleen.

Classification and Epidemiology

Among the roughly thirty-six distinct forms of amyloidosis—each traceable to a particular protein that has misfolded—AA amyloidosis occupies a defined niche as one of the fourteen systemic variants. It ranks alongside light-chain (AL), dialysis-related (Aβ2M), and transthyretin (ATTR) amyloidosis as one of the four most prevalent systemic types. The condition is driven by either inherited genetic mutations or acquired environmental triggers that cause the responsible protein to adopt an abnormal fibrillar structure. Epidemiologically, AA amyloidosis affects approximately two individuals per million per year, slightly less common than its AL counterpart, which ranges from three to thirteen per million annually. The typical age at which symptoms first emerge clusters around the mid-fifties to early sixties. In the developed world, systemic amyloidosis as a whole accounts for roughly one death in every one thousand, underscoring that while individual subtypes are rare, their collective toll is significant.

Renal Involvement

The kidneys represent one of the most frequently targeted organs in AA amyloidosis, and the damage they sustain is both specific and severe. Amyloid fibrils deposit within the glomerular capillaries and the mesangial regions, undermining the kidney's fundamental capacity to filter metabolic waste and retain plasma proteins. The clinical consequence is a progressive leakage of protein into the urine—proteinuria—that can escalate into full nephrotic syndrome, a condition in which the body loses substantial quantities of protein and accumulates excess fluid. What distinguishes AA amyloidosis from its AL counterpart in this regard is the sheer proportion of patients who reach the terminal stage: between forty and sixty percent of individuals with the AA form progress to end-stage kidney disease, ultimately requiring dialysis to sustain life. By comparison, only about twenty percent of AL amyloidosis patients follow that trajectory. The renal burden in AA disease thus represents one of the most consequential and life-altering dimensions of the condition.

Cardiac Sparing and Neurological Involvement

A notable distinction of AA amyloidosis from AL amyloidosis lies in its relative sparing of the heart. While AL deposits in cardiac tissue can produce both diastolic and systolic failure, conduction disturbances, and a restrictive filling pattern visible on echocardiography, AA amyloidosis typically leaves the myocardium largely unaffected. The neurological and gastrointestinal landscapes, however, tell a different story. Peripheral sensory neuropathy in amyloidosis follows a symmetrical, distal-to-proximal progression, and autonomic involvement can manifest as orthostatic hypotension or more insidious gastrointestinal complaints such as constipation, nausea, and early satiety. In the gut itself, amyloid accumulation may provoke weight loss, diarrhea, abdominal pain, reflux, and even bleeding. When the liver is infiltrated, serum aminotransferases and alkaline phosphatase rise in roughly a third of patients, and the organ enlarges. Malabsorption, though less frequent in AA form than in AL, can still occur as deposits erode the tips of intestinal villi, mimicking a sprue-like picture.

Diagnosis and Prognosis

Because the signs of amyloidosis are notoriously non-specific—fatigue, peripheral edema, unexplained weight loss, shortness of breath, palpitations, and lightheadedness upon standing—clinicians often struggle to connect the dots. Suspicion may arise when protein appears in the urine, when organs enlarge without an obvious cause, or when multiple peripheral nerves malfunction simultaneously. Yet the definitive answer always comes from a tissue biopsy, and the variable, multi-organ presentation means that reaching a firm diagnosis can take considerable time. Treatment strategy centers on reducing the quantity of the offending protein, which sometimes becomes achievable by identifying and managing the underlying inflammatory or genetic driver. The stakes of delay are stark: without intervention, life expectancy for systemic amyloidosis ranges from as little as six months to roughly four years. The condition has been documented in medical literature since at least 1639, yet its diagnostic ambiguity and aggressive natural history continue to pose formidable challenges for both physicians and patients.